Eisai and Merck Annouces the US FDA Approval of Lenvima for Unresectable 1L Hepatocellular Carcinoma (HCC)

 Eisai and Merck Annouces the US FDA Approval of Lenvima for Unresectable 1L Hepatocellular Carcinoma (HCC)

Eisai’s and Merck Announces EU’s Marketing Approval of Lenvima (lenvatinib mesylate) for Hepatocellular carcinoma

Shots:
  • Approval is based on positive results of Ph III REFLECT study showing improved OS, PFS and ORR
  • REFLECT results (Lenvima vs Sorafenib): mOS (13.6 vs 12.3 mos), mPFS (7.3 vs 3.6 mos); ORR (41% vs 12%) with AE ≥20% patients & SAEs ≥2%  
  • Lenvima has been approved in Japan in H1’18 for HCC and was first approved in Feb’15 for thyroid cancer

Click here to read full press release/ article | Ref: Eisai | Image:  PRNewsWire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post